Clinical Trial

Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke

Study acronym: CRIPTO-FAST
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated September 2024 completion). Its status may not reflect the trial's current state.
Summary
Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients. The use of implantable cardiac monitors (ICM) early after the CS has demonstrated benefits in the diagnostic yield, but the indication for ICM in the current guidelines remains unclear. Atrial contraction strain (ACS) evaluated by cardiac ultrasound could be of help to select the patients more prone to suffer from silent PAF. The purpose of this investigation is to conduct a randomized prospective unicentric study to evaluate the usefulness of ICM for early detection of silent PAF episodes in patients with CS. Clinical and ultrasound predictors of PAF occurrence (ACS) will be studied in order to define patients needing a closer follow-up.
Trial Details
NCT Number NCT06542770
Lead Sponsor Parc de Salut Mar
Conditions Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder, Left Atrial Dilatation, Cryptogenic Stroke
Enrollment 100 participants
Start Date 2021-01-01
Primary Completion 2024-09 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-07